SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA CancerJ Clin 2010; 60: 277300.
  • 2
    Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Suppl 1): S161S192.
  • 3
    du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol 2009; 112: 422436.
  • 4
    Valentin L, Hagen B, Tingulstad S, Eik-Nes S. Comparison of ‘pattern recognition’ and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound Obstet Gynecol 2001; 18: 357365.
  • 5
    Szpurek D, Moszynski R, Zietkowiak W, Spaczynski M, Sajdak S. An ultrasonographic morphological index for prediction of ovarian tumor malignancy. Eur J Gynaecol Oncol 2005; 26: 5154.
  • 6
    Franchi D, Maria Teresa S, Sara B, Davide R, Mario S. Ultrasound imaging compared to a multivariate predictive algorithm combining HE4 and CA 125 (ROMA) in the pre-operative assessment of adnexal masses. Ultrasound Obstet Gynecol 2011; 38 (Suppl 1): 39.
  • 7
    Timmerman D, Schwarzler P, Collins WP et al. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 1999; 13: 1116.
  • 8
    Patarca R, Freeman GJ, Singh RP et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989; 170: 145161.
  • 9
    Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 10871097.
  • 10
    Song G, Cai QF, Mao YB, Ming YL, Bao SD, Ouyang GL. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K/Akt pathway. Cancer Sci 2008; 99: 19011907.
  • 11
    Bryant CS, Munkarah AR, Kumar S et al. Reduction of hypoxia-induced angiogenesis in ovarian cancer cells by inhibition of HIF-1 alpha gene expression. Arch Gynecol Obstet 2010; 282: 677683.
  • 12
    Tilli TM, Franco VF, Robbs BK et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 2011; 9: 280293.
  • 13
    Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 2007; 14: 373381.
  • 14
    Zhang LL, Shao SL, Wu Y. Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance. Chin J Cancer 2010; 29: 2529.
  • 15
    Visintin I, Feng Z, Longton G et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14: 10651072.
  • 16
    Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol 2000; 16: 500505.
  • 17
    Amor F, Vaccaro H, Alcazar JL, Leon M, Craig JM, Martinez J. Gynecologic imaging reporting and data system: a new proposal for classifying adnexal masses on the basis of sonographic findings. J Ultrasound Med 2009; 28: 285291.
  • 18
    Alcazar JL, Merce LT, Laparte C, Jurado M, Lopez-Garcia G. A new scoring system to differentiate benign from malignant adnexal masses. Am J Obstet Gynecol 2003; 188: 685692.
  • 19
    Pencina MJ, D'Agostino RB, Sr, D'Agostino RB, Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157172. discussion 207-12.
  • 20
    Jacobs I, Bast RC, Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4: 112.
  • 21
    Malkasian GD, Jr, Knapp RC, Lavin PT et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988; 159: 341346.
  • 22
    Zygmunt A, Madry R, Markowska J, Fischer Z. Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer. Eur J Gynaecol Oncol 1999; 20: 298301.
  • 23
    Rosen DG, Wang L, Atkinson JN et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99: 267277.
  • 24
    Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 16711679.
  • 25
    Moore RG, Brown AK, Miller MC et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108: 402408.
  • 26
    Valentin L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: the contribution of Doppler ultrasound. Ultrasound Obstet Gynecol 1999; 14: 338347.
  • 27
    Moore RG, Miller MC, Steinhoff MM et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol 2012; 206: 351 e1351 e8.
  • 28
    Van Holsbeke C, Van Calster B, Testa AC et al. Prospective internal validation of mathematical models to predict malignancy in adnexal masses: results from the international ovarian tumor analysis study. Clin Cancer Res 2009; 15: 684691.
  • 29
    Van Calster B, Timmerman D, Bourne T et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 2007; 99: 17061714.
  • 30
    Amor F, Alcazar JL, Vaccaro H, Leon M, Iturra A. GI-RADS reporting system for ultrasound evaluation of adnexal masses in clinical practice: a prospective multicenter study. Ultrasound Obstet Gynecol 2011; 38: 450455.
  • 31
    Valentin L, Ameye L, Savelli L et al. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound Obstet Gynecol 2011; 38: 456465.
  • 32
    Valentin L, Jurkovic D, Van Calster B et al. Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol 2009; 34: 345354.